Conclusions The current study identifies an 18% reduction in composite kidney outcomes, a 16% decrease in kidney failure, and a 13% reduction in MACE risk in patients with type 2 diabetes prescribed GLP-1 agonists
Differentiate next-generation GLP-1s by quality of weight loss By Shipra Patel, M.D., Therapeutic Area Lead, Endocrinology, Amy Pace, ScD, Vice President, Biostatistics, Nathan Noakes, Sensor Solutions Director The rise of highly effective glucagon-like peptide-1 receptor agonists (GLP-1s) and multi-agonists has transformed obesity research into a multi-billion-dollar industry with strong momentum and fierce competition
The source of what you put in your body matters
Reducing DHT levels may help slow further hair thinning in susceptible individuals
The injections will help the body target fat deposits, especially in the liver